Recent News

Woodbridge, CT., March 12, 2008 - - GlyGenix Therapeutics, Inc has signed a license agreement with the National Institutes of Health (NIH). Under the agreement, GlyGenix Therapeutics obtains exclusive worldwide rights to the catalytic moiety of the glucose-6-phosphatase gene (G6Pase), protein and related mutations. The company agrees to pay license fees to the NIH and will perform research relating to the use of G6Pase to find a cure for Glycogen Storage Disease Type 1a.

Woodbridge, CT., April 1, 2009 - - GlyGenix Therapeutics, Inc has signed a Joint Research Agreement (JRA) with Philips Research North America Group (Philips). Under the JRA, the companies have designed a research plan that will compare the efficacy of ultrasound mediated transfection of glucose-6-phosphatase plasmid DNA into the mouse liver for curing the Glycogen Storage Disease Type 1a phenotype. The research will take place at Duke University as part of a 3 party collaboration (see below).

Woodbridge, CT., April 1, 2009 - - GlyGenix Therapeutics, Inc has signed a Sponsored Research Agreement (SRA) with Duke University, Division of Medical Genetics. The research will explore the use of Ultrasound-mediated Plasmid (USP) in vivo DNA delivery methods using the G6Pase gene to cure the GSD1a phenotype in a G6Pase mutant mouse model. The research is in collaboration with Philips Research North America Group.

Eindhoven, Netherlands, August 5, 2009 - Royal Philips Electronics (NYSE: PHG, AEX: PHI) and GlyGenix Therapeutics, Inc. (Woodbridge, Connecticut, USA) today announced a joint research agreement to explore the feasibility of using ultrasound technologies for gene therapy. In particular, the collaboration will research the treatment of Glycogen Storage Disease Type 1a (GSD-1a) in pre-clinical studies. The collaboration unites Philips' expertise in medical imaging technologies for diagnosis and minimally-invasive medical procedures with GlyGenix's expertise in correcting the genetic defect in GSD-1a.
READ MORE...

Woodbridge, CT., August 5, 2009 - Royal Philips Electronics and GlyGenix Therapeutics team up to research ultrasound-mediated gene therapy - TECHNOLOGY DETAILS